PharminLex

Evocative parts of pharma trademarks can prevail!

It is most likely that judges from the 5th and 6th Chambers of the General Court of the European Union took their breakfast or lunch together on last June 6! Indeed both these Chambers had to judge this day similar cases with quite the same history and shared their argumentation and conclusions in two judgments …

Evocative parts of pharma trademarks can prevail! Lire la suite »

Pharmaceutical logo are having a hard time before the GC

A decision of May 17, 2013, of the General Court (Case T-502/11) shows that difficulties in enforcing trademarks rights on a logo are increased when only a ‘high distinctiveness’ is raised without going deeper enough into the argumentation raised…. Mundipharma AG applied to register the following device as a Community trademark in respect of « pharmaceutical …

Pharmaceutical logo are having a hard time before the GC Lire la suite »

The E-PLEX / EPILEX case

On May 24, 2011, the General Court adopted an interesting approach for assessing the similarity between two pharmaceuticals having different therapeutic indications. The contested trademark E-PLEX specifically excluded medicines to combat diseases in connection with the central nervous system. The earlier opposed trademark EPILEX was registered for anti-epileptics. This is no surprise that the Court …

The E-PLEX / EPILEX case Lire la suite »

‘5 HTP’ cancelled for lack of distinctiveness

On March 9, 2011, the General Court confirmed that the word Community trademark ‘5 HTP’ should be cancelled because it lacked distinctiveness. The mark belonged to Longevity Health Products Inc. It was registered since January 13, 2004, in class 5 and notably for ‘pharmaceutical and veterinary products’. The General Court pointed out that ‘5 HTP’ …

‘5 HTP’ cancelled for lack of distinctiveness Lire la suite »

Pharmaceuticals similarity gets stricter?

On December 15, 2010 (TOLPOSAN vs./ TONOPAN), the General Court considered that ‘muscle relaxant, medicines containing tolperison; muscle relax ant veterinary preparations containing tolperison’  had a low degree of similarity with an ‘analgesic which soothe pain, in particular for treating headaches and migraines’. For the Court, the respective primary therapeutic indications of the goods at …

Pharmaceuticals similarity gets stricter? Lire la suite »

BOTOLIST et BOTOCYL annulées à cause du BOTOX

  Le Tribunal des Communautés a confirmé le 16 décembre 2010 la nullité des marques Communautaires BOTOLIST (appartenant à Helena Rubinstein) et BOTOCYL (de L’Oréal), couvrant des produits en classe 3, compte tenu de la notoriété des marques antérieures BOTOX (verbales et semi-figuratives). Pour le Tribunal, le public visé pourrait établir un lien avec la …

BOTOLIST et BOTOCYL annulées à cause du BOTOX Lire la suite »

The reassuring SORVIR case of the General Court

This September 13, 2010, was certainly the day when the General Court made the pharmaceutical trademarks practice feel better again by ruling that the marks SORVIR (contested CTM) and NORVIR (earlier CTM hold by Abbott Laboratories) were confusingly similar in respect of products of class 5. This solution may look quite obvious in the end …

The reassuring SORVIR case of the General Court Lire la suite »

French Customs strengthen their position on pharmaceuticals

The French Pharmaceutical Companies Association (LEEM), representing about 326 companies operating in France in the research and/or development of medicines for human use, has signed a joint declaration with French Customs on June 18, 2010. New processes of collaboration and of exchange of information result from it. An observatory of medicines has been created which …

French Customs strengthen their position on pharmaceuticals Lire la suite »